ABSTRACT
Azole fungicides were thought to have much greater affinity for the fungal cytochrome P450 enzyme, sterol 14 alpha-demthylase (CYP51) than the plant orthologue. Using purified CYP51 from the plant Sorghum bicolor L Moenech, a direct comparison of the sensitivity to the fungicides triadimenol and tebuconazole has been carried out. S. bicolor CYP51 was purified to homogenity as determined by SDS--PAGE and specific heme content. Addition of the azole fungicides triadimenol and tebuconazole induced type II spectral changes, with saturation occurring at equimolar azole/P450 concentrations. Inhibition of reconstituted activities revealed only a threefold insensitivity of the plant CYP51 compared to a fungal CYP51, from the phytopathogen Ustilago maydis, as judged by IC(50) values. The implications for fungicide mode of action and application are discussed.
Subject(s)
Cytochrome P-450 Enzyme Inhibitors , Fungicides, Industrial/pharmacology , Oxidoreductases/antagonists & inhibitors , Plant Proteins/antagonists & inhibitors , Triazoles/pharmacology , Cytochrome P-450 Enzyme System/metabolism , Escherichia coli/genetics , Fungal Proteins/antagonists & inhibitors , Fungal Proteins/metabolism , Fungicides, Industrial/metabolism , Inhibitory Concentration 50 , Oxidoreductases/metabolism , Plant Proteins/metabolism , Spectrophotometry , Sterol 14-Demethylase , Triazoles/metabolismABSTRACT
Cytochrome P450 51 (CYP51) is sterol 14alpha-demethylase, known also as Erg11p in yeast. First studied in yeast, where it is one of three CYPs in the genome, it has subsequently gained attention as the only CYP found so far in different kingdoms of life. As such it is central to considerations of CYP evolution. Recent use of CYP51-inhibiting antifungal drugs, such as fluconazole, has also been associated with dramatic CYP51 evolution to numerous resistant forms in fungal pathogens. CYP51 has also been discovered in mycobacteria where antifungal azoles have effect and might be of value against tuberculosis. Evolutionary and therapeutic aspects of CYP51 studies are discussed.